Urinary hesitancy and retention caused by ziprasidone

International Clinical Psychopharmacology

Volumn 21, Issue 1, 2006, Pages 71-72

  Xomalis, Dimitris ^a   Bozikas, Vasilis P ^a,b   Garyfallos, George ^a   Nikolaidis, Nikolas ^a   Giouzepas, John ^a   Fokas, Kostas ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Urinary hesitancy; Ziprasidone

Indexed keywords

QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CASE REPORT; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MALE; PRIORITY JOURNAL; REACTION TIME; SCHIZOPHRENIA; TREATMENT WITHDRAWAL; URINE RETENTION;

ADULT; ANTIPSYCHOTIC AGENTS; HUMANS; MALE; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; URINARY RETENTION;

EID: 31744442128     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000182117.49887.e7     Document Type: Article

References (19)

1. Addington D, Pantelis C, Bennatia I (2002). Ziprasidone vs risperidone in schizophrenia: efficacy and safety in a 8 week trial. Eur Neuropsychopharmacol 12 (suppl 3):314.
2. Anderson K-E (2000). Treatment of overactive bladder: drug mechanisms. Urology 55 (suppl 5A):51-57.
3. Arato M, O'Connor R, Meltzer H (2002). A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17:207-215.
4. Bozikas VP, Petrikis P, Karavatos A (2001). Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol 15:142-143.
5. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial in the ziprasidone study group. Neuropsychopharmacology 20:491-505.
6. Daniel DG, Copeland LF, Tamminga C, Ziprasidone (2004). In: Schatzberg AF, Nemeroff CB (editors): Textbook of Psychopharmacology, 3rd edn. Washington, DC: American Psychiatric Press; pp. 507-518.
7. Demyttenaere K, Huygens R (2002). Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. Eur Neuropsychopharmacol 12:337-341.
8. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998). An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296-304.
9. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R (2000). A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63:516-523.
10. Kapur S (2003). Modulation of dopamine D2 receptors as a basis of antipsychotic effect. In: Kapur S, Lecrubier Y (editors): Dopamine in the Pathophysiology and Treatment of Schizophrenia. London: Martin Dunitz; pp. 49-67.
11. Kasper S, El Giamal N, Higler E (2000). Reboxetine: The first selective noradrenaline re-uptake inhibitor. Exp Opin Pharmacother 1:771-782.
12. Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:17-184.
13. Norton P, Zinner N, Yalcin I, Bump RC (2002). Duloxetine Urinary Incontinence Study Group: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40-48.
14. Olie J-P, Spina E, Benattia I (2002). Ziprasidone versus amisulpride for negative symptoms of schizophrenia. Eur Neuropsychopharmacol 12 (suppl 3):313.
15. Pfizer Hellas (2003). Geodon Monograph. Athens, Greece: Pfizer Hellas Inc.
16. Puech A, Montgomery SA, Prost JF, Solles A, Briley M (1997). Milnacipram, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99-108.
17. Scates A, Doraiswamy PM (2000). Reboxetine: a selective norepinenephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34:1302-1313.
18. Simpson G, Horne RL, Weiden PJ, Pigott T, Bari M, Romano SJ (2002). Ziprasidone versus olanzapine in schizophrenia: a double-blind trial. Eur Psychiatry 17 (suppl 1):101-102.
19. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD (1999). Urinary incontinence and depression. J Urol 162:82-84.